GBS GLUCOSE BIOSENSOR SYS

DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing

DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing

Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors

“By using fingerprint drug testing, I no longer have to take people off a project for half a day for screening – we can conduct the tests there and then” – Ruth Trant, SHEQ & Assurance Director, DGP Plc

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that has selected the revolutionary portable to enable in-house drug testing.

DGP is one of the UK’s leading construction logistics, security and support companies. Its services enable the delivery of many of the country’s largest construction projects. The company implements robust processes and risk-based SHEQ management to support the way it delivers its works, and will now use the Intelligent Fingerprinting Drug Screening System to enable faster, more convenient and more flexible workplace drug testing.

“Having already seen fingerprint sweat-based drug screening in action at another company, I knew that the Intelligent Fingerprinting would work well for DGP,” explained Ruth Trant, DGP Plc’s SHEQ & Assurance Director. “We had previously used an external drug testing service to carry out random urine-based screening, but with around 450 employees and contractors working on customer project sites at any one time, this proved highly disruptive to productivity. With fingerprint sweat-based testing we can conduct the ten-minute tests there and then, with people not having to wait. The portability of the Intelligent Fingerprinting system also means we can conduct workplace testing wherever it is needed.

“We have a duty to put people to work safely, and conducting testing sends a clear signal that coming to work under the influence of drugs or alcohol is unsafe and not acceptable at DGP Plc. We are also keen for everyone across the business to see that we take our Drug and Alcohol Policy very seriously. The fact that everyone in DGP is subject to random testing is important, while its portability means that people get to see our Intelligent Fingerprinting system in action regularly,” added Ruth.

“An increasing number of construction and logistics firms are turning to our fingerprint sweat-based system for various testing needs, from recruitment and onboarding requirements to random workplace screening or for cause testing,” added Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. “Our system’s flexibility and ease of use makes it much simpler for organizations like DGP to manage workplace drug testing internally, resulting in overall cost savings and improved productivity due to minimal disruption.”

An introductory video demonstrating fingerprint-based drug testing in action is available .

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (the “Company”) (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. 

For more information, visit:  

About DGP Plc

DGP Plc is a leading UK construction logistics, security, and support service contractor with an impressive track record spanning over three decades. DGP has contributed to the delivery of a range of complex and highly regulated projects across the UK, including Manchester Airport, Paddington Square, Manchester Old Town Hall, and Birmingham New Street Station.

For more information, visit:

Forward-Looking Statements:

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact: 

Intelligent Bio Solutions Inc. 

 

|

Media Contact: 

Cheryl Billson, Comma Communications 



+44 (0)7791 720460



EN
22/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue...

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private plac...

 PRESS RELEASE

Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026...

Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Co...

 PRESS RELEASE

Intelligent Bio Solutions Initiates Additional Clinical Studies for FD...

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasi...

 PRESS RELEASE

Intelligent Bio Solutions Announces Closing of $10.0 Million Private P...

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to ...

 PRESS RELEASE

Intelligent Bio Solutions Announces $10.0 Million Private Placement Pr...

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch